ASX:PYCBiotechs
PYC Therapeutics (ASX:PYC) Names New CFO As Investors Weigh A Pricey Valuation
PYC Therapeutics (ASX:PYC) drew investor attention after appointing Thomas Ulmer as Chief Financial Officer, adding biotechnology and pharmaceuticals finance experience that includes guiding Immatics N.V. through its listing as a US biotechnology company.
See our latest analysis for PYC Therapeutics.
Beyond the CFO appointment, PYC Therapeutics has seen a 31.78% 1 month share price return and a 32.34% 3 month share price return, while its 3 year total shareholder return of 131.44% points to...